Molecular Formula | C17H16N2O3 |
Molar Mass | 296.32 |
Density | 1.363±0.06 g/cm3(Predicted) |
Melting Point | >222°C (dec.) |
Boling Point | 592.6±50.0 °C(Predicted) |
Solubility | DMSO: soluble10mg/mL (clear solution) |
Appearance | powder |
Color | light orange to dark orange |
pKa | 4.60±0.10(Predicted) |
Storage Condition | -20°C |
Stability | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months. |
In vitro study | SU5402 inhibited VEGF-,FGF-, and PDGF-dependent cell proliferation with an IC50 of 0.05 μm, 2.80 μm, and 28.4 μm, respectively. In HUVECs, SU5416 selectively inhibited VEGF-driven mitogenesis in a dose-dependent manner with an IC50 of 0.04 μm. In Nasopharyngeal Epithelial Cells, SU5402 attenuates lmp1-mediated aerobic glycolysis, cell transformation, cell migration, and invasion. In mouse C3H10T1/2 cells, SU 5402 reduced the effect of FGF23 on cell differentiation. |
In vivo study | In mice, SU5416 (25 mg/kg, I. p.) inhibited the subcutaneous growth of a panel of cancer cell lines by inhibiting the angiogenic processes associated with tumor growth. |
WGK Germany | 3 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 3.375 ml | 16.874 ml | 33.747 ml |
5 mM | 0.675 ml | 3.375 ml | 6.749 ml |
10 mM | 0.337 ml | 1.687 ml | 3.375 ml |
5 mM | 0.067 ml | 0.337 ml | 0.675 ml |
biological activity | SU5402 is an effective multi-target receptor kinase inhibitor with IC50 for VEGFR2,FGFR1, and PDGF-Rβ of 20 nM,30 nM, and 510 nM respectively. |
target | TargetValue VEGFR2 (Cell-Free Assay) 20 nM FGFR1 (Cell-Free Assay) 30 nM PDGFRβ (Cell-Free Assay) 510 nM |
Target | Value |
VEGFR2 (Cell-free assay) | 20 nM |
FGFR1 (Cell-free assay) | 30 nM |
PDGFRβ (Cell-free assay) | 510 nM |
in vitro study | SU5402 inhibited VEGF-,FGF-,PDGF-dependent cell proliferation with IC50 of 0.05 μM,2.80 μM and 28.4 μM respectively. In HUVECs, SU5416 selectively inhibits VEGF-driven mitosis in a metered-dependent manner with an IC50 of 0.04 μM. In nasopharyngeal epithelial cells, SU5402 attenuates LMP1-mediated aerobic glycolysis, cell transformation, cell migration, and invasion. In mouse C3H10T1/2 cells, SU 5402 reduce the effect of FGF23 on cell differentiation. |
in vivo studies | in mice, SU5416 (25 mg/kg, I. p.) inhibits the subcutaneous growth of a group of cancer cell lines by inhibiting the angiogenesis process associated with tumor growth. |